Under construction – not a live service
Sign in
Taking people in TürkiyeNo phase

Compares two heart-bypass machine methods during heart surgery in adults

Compares a minimally invasive bypass circuit with standard bypass in adults having heart surgery.

Key facts

Who runs it
Aristotle University Of Thessaloniki
Where
Ankara, Izmir, and Rize, TürkiyeSee the 3 sitesAlso in 5 other countries, 10 sites
Trial code
Registry title
MiECC Versus Conventional Cardiopulmonary Bypass in Cardiac Surgery (MiECS)
Status
Recruiting
People taking part
1,300 people, planned
Started
26 May 2022
Expected to end
31 Mar 2029
Type of study
Interventional, 2 groupsOne group gets an existing treatment, for comparison.
Treatments tested
  • Minimal Invasive Extracorporeal Circulation
  • Conventional cardiopulmonary bypass
Record updated
30 March 2026

Who can take part

AI summary

From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.

The trial is looking for adults having planned or urgent heart surgery (bypass grafting, aortic valve replacement, or both) using a heart-lung machine, to compare two types of machine.

Age
18 to 85 years
Sex
All sexes can join.
Disease stage
Coronary artery disease or aortic valve stenosis needing elective or urgent coronary artery bypass grafting (CABG), aortic valve replacement (AVR) or CABG+AVR surgery, without circulatory arrest.

Main reasons for not taking part

  • Emergency or salvage operation
  • Major aortic surgery, for example aortic root replacement
  • Cannot or will not accept blood product transfusion, for example Jehovah's Witnesses
  • Inherited or acquired platelet, red cell or clotting disorders (iron deficiency anaemia is allowed)
  • Unable to give informed consent, for example because of learning or language difficulties

The registry criteria, word for word

Show all 6 criteriaShow less

Who can take part

  • All patients undergoing any elective or urgent coronary artery bypass grafting (CABG), aortic valve replacement (AVR) or CABG+AVR surgery using extracorporeal circulation without circulatory arrest

Who cannot take part

  • Requirement for major aortic surgery (e.g. aortic root replacement)
  • Congenital or acquired platelet, red cell or clotting disorders (patients with iron deficient anaemia will not be excluded)
  • Requirement for emergency or salvage operation
  • Contraindication or objection (e.g. Jehovah's Witnesses) to transfusion of blood products
  • Inability to give informed consent for the study (e.g. learning or language difficulties)

Check if you might fit

Answer for yourself. This is not a decision: only the study team can say whether you can take part.

  • Are you between 18 and 85 years old?

Where in Türkiye

Also in 5 other countries, 10 sites

  • Department of Cardiovascular Surgery, Ankara City HospitalAnkara, TürkiyeContact: Georgios Papazisis, Assoc. Prof.No longer taking part
  • Department of Cardiovascular Surgery, Izmir Bakırçay University, Faculty of MedicineIzmir, TürkiyeContact: Ahmet Daylan, Ass. Prof.Taking people
  • Department of Cardiovascular Surgery, Faculty of Medicine, Recep Tayyip Erdoğan UniversityRize, TürkiyeContact: Doğuş Hemşinli, Associate ProfessorTaking people

About the trial

What the trial wants to find out

MiECS is one of the largest multicentre randomised controlled trials on extracorporeal circulation conducted under the auspices of Minimal Invasive Extracorporeal Technologies International Society (MiECTiS). It is designed to ultimately address the emerging effectiveness of MiECC systems in the light of modern perfusion practice worldwide. The primary hypothesis is that MiECC, as compared to conventional CPB (cCPB), reduces the proportion of patients experiencing serious perfusion-related postoperative morbidity after cardiac surgery. The study will be led by the Clinical Research Unit of the Special Unit for Biomedical Research and Education (SUBRE), Aristotle University of Thessaloniki School of Medicine in Greece (AUSoM) with Chief Investigator Professor Kyriakos Anastasiadis, who is a key-opinion-leader in the field of MiECC, founder and Executive Board of MiECTiS.

The 2 groups in the trial

  • Minimal Invasive Extracorporeal Circulation (MiECC)Existing treatment, for comparison

    Patients undergoing coronary artery bypass grafting (CABG), aortic valve replacement (AVR), or combined procedure (AVR+CABG) with Minimal Invasive Extracorporeal Circulation (MiECC).

    Treatment: Minimal Invasive Extracorporeal Circulation

  • Conventional Cardiopulmonary Bypass (cCPB)Existing treatment, for comparison

    Patients undergoing coronary artery bypass grafting (CABG), aortic valve replacement (AVR), or combined procedure (AVR+CABG) with conventional cardiopulmonary bypass (cCPB)

    Treatment: Conventional cardiopulmonary bypass

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Print a page for my doctor

Data and sources

Registry record
Listed on ClinicalTrials.gov.
Official title
Minimally Invasive Extracorporeal Circulation Versus Conventional Cardiopulmonary Bypass in Patients Undergoing Cardiac Surgery (MiECS): a Randomised Controlled Trial
Plain-language title
Compares two heart-bypass machine methods during heart surgery in adultsGenerated from the registry record. The registry title is the official one.
AI summary
From the trial's eligibility criteria. Read by machine on 12 November 2026.
Fit questions
Built from NCT05487612, who can take part
Record updated
30 March 2026